Takeiwa Toshihiko, Ikeda Kazuhiro, Mitobe Yuichi, Horie-Inoue Kuniko, Inoue Satoshi
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama 350-1241, Japan.
Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan.
Cancers (Basel). 2020 May 31;12(6):1424. doi: 10.3390/cancers12061424.
Long noncoding RNAs (lncRNAs) are defined as RNAs longer than 200 nucleotides that do not encode proteins. Recent studies have demonstrated that numerous lncRNAs are expressed in humans and play key roles in the development of various types of cancers. Intriguingly, some lncRNAs have been demonstrated to be involved in endocrine therapy resistance for breast cancer through their own mechanisms, suggesting that lncRNAs could be promising new biomarkers and therapeutic targets of breast cancer. Here, we summarize the functions and mechanisms of lncRNAs related to the endocrine therapy resistance of breast cancer.
长链非编码RNA（lncRNAs）被定义为长度超过200个核苷酸且不编码蛋白质的RNA。最近的研究表明，大量lncRNAs在人类中表达，并在各种类型癌症的发展中发挥关键作用。有趣的是，一些lncRNAs已被证明通过其自身机制参与乳腺癌的内分泌治疗耐药性，这表明lncRNAs可能是有前景的乳腺癌新生物标志物和治疗靶点。在此，我们总结了与乳腺癌内分泌治疗耐药性相关的lncRNAs的功能和机制。
